|
Market Closed -
NYSE
21:00:02 21/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 19.10 USD | -19.58% |
|
-15.15% | -19.85% |
| 10-21 | Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating | MT |
| 10-20 | Arcus Biosciences, Inc. - Special Call |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,024 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 2.57% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 2,584 | 2,922 | 2,719 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 25.02% | 13.1% | -6.95% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -6.7x | -7.14x | -7.75x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 11x | -33x | 8.28x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.86x | 1.17x | 0.98x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 41.3x | 53.5x | 20x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 35.3x | 51.7x | 18x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -5.75x | -6.32x | -8.15x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -5.47x | -6.54x | -6.03x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -6.82x | -7.94x | -7.54x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -14.7% | -12.6% | -13.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.545 | -3.328 | -3.064 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 73.15 | 56.52 | 150.9 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -449.4 | -462 | -333.7 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -472.3 | -446.9 | -451.1 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -448.9 | -413.2 | -401.4 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -440.6 | -102.2 | -305.4 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 23.75 | 23.75 | 23.75 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 127,333 | - | - |
| Announcement Date | 23/02/22 | 28/02/23 | 21/02/24 | 25/02/25 | 25/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.72x | 34.77x | -5.79x | -.--% | 3.02B | |
| 19.21x | 6.83x | 13.69x | 1.55% | 66.34B | |
| 36.32x | 6.47x | 19.31x | 0.89% | 52.92B | |
| 29.51x | 8.11x | 25.65x | 0.05% | 54.82B | |
| 34.13x | 3.33x | 14.37x | -.--% | 44.09B | |
| 50.62x | 5.85x | 32.15x | -.--% | 43.72B | |
| -20.41x | 209.35x | -21.69x | -.--% | 42.13B | |
| 29.48x | 8.35x | 21.6x | 0.36% | 33.96B | |
| 30.25x | 6.41x | 16.63x | -.--% | 26.17B | |
| 31.94x | 5.89x | 19.81x | -.--% | 23.37B | |
| Average | 23.43x | 29.54x | 13.57x | 0.28% | 39.05B | |
| Weighted average by Cap. | 26.09x | 28.57x | 15.56x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
